ArticleBMC pharmacology & toxicology2020

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.

Fabian Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.